Takeda presenta resultados positivos preliminares del ensayo pivotal de fase 2/3 de TAK-881 en inmunodeficiencia primaria (IDP)
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in